Skip to content Skip to navigation

Liquid Biopsy Proteomics in Ophthalmology.

TitleLiquid Biopsy Proteomics in Ophthalmology.
Publication TypeJournal Article
Year of Publication2024
AuthorsWolf, Julian, Franco Joel A., Yip Rui, Dabaja Mohamed Ziad, Velez Gabriel, Liu Fei, Bassuk Alexander G., Mruthyunjaya Prithvi, Dufour Antoine, and Mahajan Vinit B.
JournalJ Proteome Res
Volume23
Issue2
Pagination511-522
Date Published2024 Feb 02
ISSN1535-3907
KeywordsArtificial Intelligence, Biopsy, Humans, Liquid Biopsy, Ophthalmology, Proteins, Proteomics
Abstract

Minimally invasive liquid biopsies from the eye capture locally enriched fluids that contain thousands of proteins from highly specialized ocular cell types, presenting a promising alternative to solid tissue biopsies. The advantages of liquid biopsies include sampling the eye without causing irreversible functional damage, potentially better reflecting tissue heterogeneity, collecting samples in an outpatient setting, monitoring therapeutic response with sequential sampling, and even allowing examination of disease mechanisms at the cell level in living humans, an approach that we refer to as TEMPO (Tracing Expression of Multiple Protein Origins). Liquid biopsy proteomics has the potential to transform molecular diagnostics and prognostics and to assess disease mechanisms and personalized therapeutic strategies in individual patients. This review addresses opportunities, challenges, and future directions of high-resolution liquid biopsy proteomics in ophthalmology, with particular emphasis on the large-scale collection of high-quality samples, cutting edge proteomics technology, and artificial intelligence-supported data analysis.

DOI10.1021/acs.jproteome.3c00756
Alternate JournalJ Proteome Res
PubMed ID38171013
PubMed Central IDPMC10845144
Grant ListP30 EY026877 / EY / NEI NIH HHS / United States
R01 EY030151 / EY / NEI NIH HHS / United States
R01 EY031360 / EY / NEI NIH HHS / United States
R01 EY031952 / EY / NEI NIH HHS / United States